Cytomedix AutoloGel(TM) Registry to Be Featured at the Symposium on Advanced Wound Care (SAWC-SPRING) on May 5, 2013

GAITHERSBURG, MD--(Marketwired - May 2, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that AutoloGel will be featured in oral and poster presentations at the Symposium on Advanced Wound Care (SAWC), that is being held in Denver, Colorado on May 1- 5, 2013. Dr. Caroline Fife, Chief Medical Officer of Intellicure and Medical Director at the St. Luke's Episcopal Hospital The Woodlands Center for Wound Healing, will deliver the oral presentation.

Presentation Details

Time: Saturday, May 5, 2013 from 4:30pm-5:30pm

Abstract #: Oral - 40.4 Poster - CR-23

Title: Harnessing Electronic Medical Record Capabilities for Prospective Clinical Research: The Platelet Rich Plasma (PRP) Registry for Coverage with Evidence Development (CED)

Location: Colorado Convention Center, Denver, Colorado

Dr. Fife's oral presentation will outline the benefits of the EHR (electronic health record) system that is being used in the CED (Coverage with Evidence Development) program for AutoloGel.An EHR system with structured language has been customized to automatically perform the acquisition of data and verification of source in both the randomized trial and non-randomized cohort trials that make up the AutoloGel CED program. Only wound centers utilizing this EHR or who can adapt to it will be able to participate in the program.

The presentation and poster will describe the benefits of using an EHR system for patient recruitment, data management and integrity, and data analysis. Dr. Fife will discuss how an EHR can decrease the cost of a clinical trial, reduce time needed by site staff and monitors, increase data accuracy, reduce training required for investigators and improve safety in monitoring. A well-designed system improves overall data analysis and ensures adequate power in a clinical trial by delivering essentially real time results.

The Centers for Medicare and Medicaid Services (CMS) has agreed to provide reimbursement coverage for AutoloGel in patients with non-healing ulcers under the Coverage with Evidence Development (CED) program. CED is a determination made by the CMS that a medical product is reasonable and necessary, based on the best available clinical data, but where the evidence base has not yet been sufficiently developed.

About the SAWC-SPRINGThe Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) meeting is the premier interdisciplinary wound care program within this clinical field and is the largest annual gathering of wound care clinicians in the United States.More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend the 2013 SAWC Spring/WHS meeting.

Read more:
Cytomedix AutoloGel(TM) Registry to Be Featured at the Symposium on Advanced Wound Care (SAWC-SPRING) on May 5, 2013